<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="109337">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01971164</url>
  </required_header>
  <id_info>
    <org_study_id>AZ951-U-12-004</org_study_id>
    <nct_id>NCT01971164</nct_id>
  </id_info>
  <brief_title>Safety, Tolerability, PK &amp; PD Study of JTZ-951 in Anemic Subjects With End-stage Renal Disease</brief_title>
  <official_title>Randomized, Single-blind, Placebo-controlled, Multiple Ascending Dose Study to Evaluate Safety, Tolerability, Pharmacokinetics &amp; Pharmacodynamics of JTZ-951 Administered Once Daily for 15 Days in Anemic Subjects With End-stage Renal Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Akros Pharma Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Akros Pharma Inc.</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine the safety, tolerability, pharmacokinetics (PK),
      and pharmacodynamics (PD) of sequential ascending doses of JTZ-951 administered for 15 days
      in anemic subjects with end-stage renal disease (ESRD) receiving hemodialysis.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>May 2013</start_date>
  <completion_date type="Anticipated">August 2014</completion_date>
  <primary_completion_date type="Anticipated">July 2014</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Number of subjects with adverse events</measure>
    <time_frame>15 days</time_frame>
    <safety_issue>Yes</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>Vital signs and 12 lead ECGs</measure>
    <time_frame>15 days</time_frame>
    <safety_issue>Yes</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>Cmax (maximum concentration)</measure>
    <time_frame>15 days</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>tmax (time to reach maximum concentration)</measure>
    <time_frame>15 days</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>t1/2 (elimination half-life)</measure>
    <time_frame>15 days</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>AUC (area under the concentration-time curve)</measure>
    <time_frame>15 days</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>AR (accumulation ratio)</measure>
    <time_frame>15 days</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>RBC (red blood cell) count</measure>
    <time_frame>15 days</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>Hgb (hemoglobin)</measure>
    <time_frame>15 days</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>TSAT (transferrin saturation)</measure>
    <time_frame>15 days</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>serum ferritin</measure>
    <time_frame>15 days</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">32</enrollment>
  <condition>Anemia of Chronic Kidney Disease</condition>
  <arm_group>
    <arm_group_label>Dose 1 JTZ-951 or Placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Tablets, 1 dose per day for 15 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose 2 JTZ-951 or Placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Tablets, 1 dose per day for 15 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose 3 JTZ-951 or Placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Tablets, 1 dose per day for 15 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose 4 JTZ-951 or Placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Tablets, 1 dose per day for 15 days</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>JTZ-951</intervention_name>
    <description>Subjects will receive JTZ-951 or Placebo</description>
    <arm_group_label>Dose 1 JTZ-951 or Placebo</arm_group_label>
    <arm_group_label>Dose 2 JTZ-951 or Placebo</arm_group_label>
    <arm_group_label>Dose 3 JTZ-951 or Placebo</arm_group_label>
    <arm_group_label>Dose 4 JTZ-951 or Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Dose 1 JTZ-951 or Placebo</arm_group_label>
    <arm_group_label>Dose 2 JTZ-951 or Placebo</arm_group_label>
    <arm_group_label>Dose 3 JTZ-951 or Placebo</arm_group_label>
    <arm_group_label>Dose 4 JTZ-951 or Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subjects who have ESRD and have been receiving maintenance hemodialysis for at least
             12 weeks prior to the Screening Visit

          -  Body weight (post-dialysis weight) greater than 45.0 kg and a body mass index between
             20.0 and 40.0 kg/m2 (inclusive) at the Screening Visit

          -  Hemoglobin value as defined in the protocol

          -  Meet the erythropoiesis-stimulating agent (ESA) therapy criteria at the Screening
             Visit as defined in the protocol

        Exclusion Criteria:

          -  Transferrin saturation and ferritin levels at the Screening Visit as defined in the
             protocol

          -  Anemia due to known causes other than chronic kidney disease

          -  Known history of hyporesponsiveness to ESAs

          -  Acute coronary syndrome (e.g., myocardial infarction) within 1 year prior to
             Screening visit
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hideyuki Yamamoto</last_name>
    <role>Study Chair</role>
    <affiliation>Akros Pharma Inc.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Hideyuki Yamamoto</last_name>
    <phone>609-919-6111</phone>
    <email>yamamoto@akrospharma.com</email>
  </overall_contact>
  <location>
    <facility>
      <address>
        <city>Lakewood</city>
        <state>Colorado</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Saint Paul</city>
        <state>Minnesota</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2014</verification_date>
  <lastchanged_date>March 15, 2014</lastchanged_date>
  <firstreceived_date>October 15, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>anemia</keyword>
  <keyword>chronic kidney disease</keyword>
  <keyword>hemodialysis</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>No</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Anemia</mesh_term>
    <mesh_term>Kidney Diseases</mesh_term>
    <mesh_term>Kidney Failure, Chronic</mesh_term>
    <mesh_term>Renal Insufficiency, Chronic</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
